Affiliation:
1. Department of Stomatology, Sichuan Provincial People's Hospital University of Electronic Science and Technology of China Chengdu Sichuan China
2. Department of Laboratory Medicine, Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital Chengdu Sichuan China
Abstract
AbstractThere are few effective therapeutic strategies for temporomandibular joint osteoarthritis (TMJOA) due to the unclear pathology and mechanisms. We aimed to confirm the roles of GPX4 and ferroptosis in TMJOA progression. ELISA assay was hired to evaluate concentrations of ferroptosis‐related markers. The qRT‐PCR assay was hired to assess gene mRNA level. Western blot assay and immunohistochemistry were hired to verify the protein level. CCK‐8 assay was hired to detect cell viability. Human fibroblast‐like synoviocytes (FLSs) were cultured to confirm the effects of GPX4 and indicated inhibitors, and further verified the effects of GPX4 and ferroptosis inhibitors in TMJOA model rats. Markers of ferroptosis including 8‐hidroxy‐2‐deoxyguanosine (8‐OHdG) and iron were notably increased in TMJOA tissues and primary OA‐FLSs. However, the activity of the antioxidant system including the glutathione peroxidase activity, glutathione (GSH) contents, and glutathione/oxidized glutathione (GSH/GSSG) ratio was notably inhibited in TMJOA tissues, and the primary OA‐FLSs. Furthermore, the glutathione peroxidase 4 (GPX4) expression was down‐regulated in TMJOA tissues and primary OA‐FLSs. Animal and cell experiments have shown that ferroptosis inhibitors notably inhibited ferroptosis and promoted HLS survival as well as up‐regulated GPX4 expression. Also, GPX4 knockdown promoted ferroptosis and GPX4 overexpression inhibited ferroptosis. GPX4 also positively regulated cell survival which was the opposite with ferroptosis. In conclusion, GPX4 and ferroptosis regulated the progression of TMJOA. Targeting ferroptosis might be an effective therapeutic strategy for TMJOA patients in the clinic.
Funder
National Natural Science Foundation of China